Login to Your Account



Gilead Pays Big For Myogen: $2.5B Gets PAH Drug, More

By Randall Osborne


Tuesday, October 3, 2006
Gilead Sciences Inc. plans to pluck the steadily ripening mid-cap Myogen Inc. for about $2.5 billion, a takeover that would add the Phase III headliner ambrisentan for pulmonary arterial hypertension to Gilead's pipeline, as well as the less celebrated - but potentially at least as valuable - darusentan for resistant high blood pressure. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription